4242 Campus Point Court
Tocagen is developing first-in-class, broadly applicable product candidates for the treatment of cancer using our cancer-selective gene therapy platform built on retroviral replicating vectors, or RRVs, initially for patients with recurrent high grade glioma, or HGG.
Our broadly applicable product candidates are designed to activate a patient’s immune system against their own cancer from within.
At the core of our approach is a gene therapy platform that utilizes RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed.
Stock Symbol: TOCA
Stock Exchange: NASDAQ
This animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Toca 511 & Toca FC is an investigational therapy, which has not been proven to be safe or effective for any use and is not approved by the U.S. Food and Drug Administration or any other government agency.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC. The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.
95 articles with Tocagen
Interim Data Show Increased Median Overall Survival Of Recurrent Brain Cancer Patients Treated With Tocagen Inc.'s Toca 511 & Toca FC, Compared To Published Benchmarks
Tocagen Inc. To Present Toca 511 Data At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology
Data for Tocagen Inc.'s Toca 511 Presented At The American Society Of Gene And Cell Therapy Annual Meeting
Data Presented At Society For Neuro-Oncology Annual Meeting Demonstrate Tocagen Inc.'s Toca 511 Gene Therapy With Toca FC Was Well Tolerated And Showed Antitumor Activity In Patients With High Grade Glioma
Voices Against Brain Cancer Awards Grant to Tocagen Inc. to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
Advancing Neuroscience: IMRIS, MRI Interventions, Inc. and Tocagen Inc. Combine Technologies to Precisely Deliver Potential Cancer-Fighting Drug to Brain Tumors
MRI Interventions, Inc. Release: Tocagen Inc. to Utilize ClearPoint® Neuro Intervention System for MRI-guided Delivery of Toca 511 in a Study of Patients With Brain Cancer
Siemens Healthcare Diagnostics Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen Inc.
Tocagen Inc. Release: Study Published in Neuro-Oncology Journal Shows Brain Tumor Eradication and Prolonged Survival in Mice Treated With Toca 511 and 5-FC